1. Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical review. Hum Reprod Update 2015; 21 (6): 762–78.
2. Osayande AS, Mehulic S. Diagnosis and initial management of dysmenorrhea. Am Fam Physician 2014; 89 (5): 341–6.
3. Mrugacz G, Grygoruk C, Sieczyński P et al. Etiopathogenesis of dysmenorrhea. Med Wieku Rozwoj 2013; 17 (1): 85–9.
4. Ortiz MI. Primary dysmenorrhea among Mexican university students: prevalence, impact and treatment. Eur J Obstet Gynecol Reprod Biol 2010; 152 (1): 73–7.
5. Wong LP, Khoo EM. Dysmenorrhea in a multiethnic population of adolescent Asian girls. Int J Gynaecol Obstet 2010; 108 (2): 139–42.
6. Pitangui AC, Gomes MR, Lima AS et al. Menstruation disturbances: prevalence, characteristics, and effects on the activities of daily living among adolescent girls from Brazil. J Pediatr Adolesc Gynecol 2013; 26: 148–52.
7. Ayan M, Sogut E, Tas U et al. Pain levels associated with renal colic and primary dysmenorrhea: a prospective controlled study with objective and subjective outcomes. Arch Gynecol Obstet 2012; 286: 403–9.
8. Jones AE. Managing the pain of primary and secondary dysmenorrhoea. Nurs Times 2004; 100 (10): 40–3.
9. Ju H, Jones M, Mishra G. The prevalence and risk factors of dysmenorrhea. Epidemiol Rev 2014; 36: 104–13.
10. Berkley KJ, McAllister SL. Don’t dismiss dysmenorrhea! Pain 2011; 152: 1940–1.
11. Pejčić A, Janković S. Risk factors for dysmenorrhea among young adult female university students. Ann Ist Super Sanita 2016; 52 (1): 98–103.
12. Ju H, Jones M, Mishra G. A U-Shaped Relationship between Body Mass Index and Dysmenorrhea: A Longitudinal Study. PLoS One 2015; 10 (7).
13. Iacovides S, Baker FC, Avidon I, Bentley A. Women with dysmenorrhea are hypersensitive to experimental deep muscle pain across the menstrual cycle. J Pain 2013; 14 (10): 1066–76.
14. Vincent K, Warnaby C, Stagg CJ et al. Dysmenorrhoea is associated with central changes in otherwise healthy women. Pain 2011; 152: 1966–75.
15. Ye R, Wang S, Li Y et al. Primary dysmenorrhea is potentially predictive for initial orthodontic pain in female patients. Angle Orthod 2014; 84 (3): 424–9.
16. Juang CM, Yen MS, Twu NF et al. Impact of pregnancy on primary dysmenorrhea. Int J Gynaecol Obstet 2006; 92 (3): 221–7.
17. Ju H, Jones M, Mishra G. The prevalence and risk factors of dysmenorrhea. Epidemiol Rev 2014; 36: 104–13.
18. Hayaishi O, Matsumura H. Prostaglandins and sleep. Adv Neuroimmunol 1995; 5: 211–6.
19. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol 2006; 108: 428–41.
20. Coco AS. Primary dysmenorrhea. Am Fam Physician 1999; 60: 489–96.
21. Nigam S, Benedetto C, Zonca M et al. Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. Eicosanoids 1991; 4 (3): 137–41.
22. Harel Z. Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea. J Pediatr Adolesc Gynecol 2004; 17: 75–9.
23. Altunyurt S, Gol M, Altunyurt S et al. Primary dysmenorrhea and uterine blood flow: a color Doppler study. J Reprod Med 2005; 50: 251–5.
24. Loram LC, Mitchell D, Skosana M, Fick LG. Tramadol is more effective than morphine and amitriptyline against ischaemic pain but not thermal pain in rats. Pharmacol Res 2007; 56: 80–5.
25. Tu CH, Niddam DM, Chao HT et al. Abnormal cerebral metabolism during menstrual pain in primary dysmenorrhea. Neuroimage 2009; 47: 28–35.
26. Tu CH, Niddam DM, Chao HT et al. Brain morphological changes associated with cyclic menstrual pain. Pain 2010; 150: 462–8.
27. Ma H, Hong M, Duan J et al. Altered cytokine gene expression in peripheral blood monocytes across the menstrual cycle in primary dysmenorrhea: a case-control study. PLoS One 2013; 8.
28. Iacovides S, Avidon I, Bentley A, Baker FC. Reduced quality of life when experiencing menstrual pain in women with primary dysmenorrhea. Acta Obstet Gynecol Scand 2014; 93: 213–7.
29. Driver HS, Baker FC. Menstrual factors in sleep. Sleep Med Rev 1998; 2: 213–29.
30. Chantler I, Mitchell D, Fuller A. Actigraphy quantifies reduced voluntary physical activity in women with primary dysmenorrhea. J Pain 2009; 10: 38–46.
31. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 163: 2433–45.
32. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum 2008; 37: 339–52.
33. Woolf CJ. Central sensitization: uncovering the relation between pain and plasticity. Anesthesiol 2007; 106: 864–7.
34. Engeler DS, Baranowski AP, Dinis-Oliveira P et al; The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development. Eur Urol 2013; 64 (3): 431–9.
35. Ortiz MI, Cortés-Márquez SK, Romero-Quezada LC et al. Effect of a physiotherapy program in women with primary dysmenorrhea. Eur J Obstet Gynecol Reprod Biol 2015; 194: 24–9.
36. Yu S, Yang J, Yang M et al. Application of acupoints and meridians for the treatment of primary dysmenorrhea: a data mining-based literature study. Evid Based Complement Alternat Med 2015; 752194.
37. Shah M, Monga A, Patel S et al. The effect of hypnosis on dysmenorrhea. Int J Clin Exp Hypn 2014; 62 (2): 164–78.
38. Ziaei S, Zakeri M, Kazemnejad A. A randomised controlled trial of vitamin E in the treatment of primary dysmenorrhoea. BJOG 2005; 112 (4): 466–9.
39. Zekavat OR, Karimi MY, Amanat A, Alipour F. A randomised controlled trial of oral zinc sulphate for primary dysmenorrhea in adolescent females. Aust N Z J Obstet Gynaecol 2015; 55 (4): 369–73.
40. Zahradnik HP, Hanjalic-Beck A, Groth K. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception 2010; 81: 185–96.
41. Campbell MA, McGrath PJ. Non-pharmacologic strategies used by adolescents for the management of menstrual discomfort. Clin J Pain 1999; 15: 313–20.
42. Sherif BQ, Al-Zohyri AM, Shihab SS. Effects of Some Non Steroidal Anti-inflammatory Drugs on Ovulation in Women with Mild Musculoskeletal Pain (A Clinical Study). IOSR-JPBS 2014; 9 (4; Ver. IV): 43–9.
43. Mendonça LL, Khamashta MA, Nelson-Piercy C et al. Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology (Oxford) 2000; 39 (8): 880–2.
44. Lindh I, Milsom I. The influence of intrauterine contraception on the prevalence and severity of dysmenorrhea: a longitudinal population study. Hum Reprod 2013; 28: 1953–60.
45. Ekelund M, Melander M, Gemzell-Danielsson K. Intrauterine contraception: attitudes, practice, and knowledge among Swedish health care providers. Contraception 2014; 89: 407–12.
46. Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev 2001.
47. Ruoff G, Lema M. Strategies in pain management: new and potential indications for COX-2 specific inhibitors. J Pain Symptom Manage 2003; 25: S21–S31.
48. Strowitzki T, Kirsch B, Elliesen J. Efficacy of ethinylestradiol 
20 mg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study. J Fam Plann Reprod Health Care 2012; 38: 94–101.
49. Harada T, Momoeda M, Terakawa N et al. Evaluation of a low-dose oral contraceptive pill for primary dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2011; 95 (6): 1928–31.
50. Ottová B, Weiss P. Mental changes in women due to the use of hormonal contraception. [Article in Czech]. Ceska Gynekol 2015; 80 (5): 355–9.
51. Cheslack-Postava K, Keyes KM, Lowe SR, Koenen KC. Oral contraceptive use and psychiatric disorders in a nationally representative sample of women. Arch Womens Ment Health 2015; 18 (1): 103–11.
52. Tanaka Y, Mori T, Ito F et al. Effects of low-dose combined drospirenone-ethinylestradiol on perimenstrual symptoms experienced by women with endometriosis. Int J Gynaecol Obstet 2016. pii: S0020-7292(16)30256-9.
53. Momoeda M, Hayakawa M, Shimazaki Y et al. Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women. Int J Womens Health 2014; 6: 989–98.
54. Zelenay S, Reis E, Sousa C. Reducing prostaglandin E2 production to raise cancer immunogenicity. Oncoimmunology 2016; 5 (5): e1123370.
55. Eberhart CE, Coffey RJ, Radhika A et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107 (4): 1183–8.
56. Pockaj BA, Basu GD, Pathangey LB et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 2004; 11 (3): 328–39.
57. Wallace AE, Sales KJ, Catalano RD et al. Prostaglandin F2alpha-F-prostanoid receptor signaling promotes neutrophil chemotaxis via chemokine (C-X-C motif) ligand 1 in endometrial adenocarcinoma. Cancer Res 2009; 69 (14): 5726–33.
58. Tong BJ, Tan J, Tajeda L et al. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia 2000; 2 (6): 483–90.
59. Jabbour HN, Milne SA, Williams AR et al. Expression of COX-2 and PGE synthase and synthesis of PGE(2) in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br J Cancer 2001; 85 (7): 1023–31.
60. Wallace AE, Gibson DA, Saunders PT, Jabbour HN. Inflammatory events in endometrial adenocarcinoma. J Endocrinol 2010; 206 (2): 141–57.
61. Babic A, Cramer DW, Titus LJ et al. Menstrual pain and epithelial ovarian cancer risk. Cancer Causes Control 2014; 25 (12): 1725–31.
62. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol 2015; 16 (9): 1061–70.
63. Beral V, Doll R, Hermon C et al.; Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371 (9609): 303–14.
64. McLaughlin JR, Risch HA, Lubinski J et al. Hereditary Ovarian Cancer Clinical Study Group. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007; 8 (1): 26–34.
65. Bosetti C, Bravi F, Negri E, La Vecchia C. Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Reprod Update 2009; 15 (5): 489–98.
66. Bird CC, McElin TW, Manalo-Estrella P. The elusive adenomyosis of the uterus-revisited. Am J Obstet Gynecol 1972; 112: 583–93.
67. Lee NC, Dicker RC, Rubin GL, Ory HW. Confirmation of the preoperative diagnoses for hysterectomy. Am J Obstet Gynecol 1984; 150: 283–7.
68. Barrier BF, Malinowski MJ, Dick EJ Jr et al. Adenomyosis in the baboon is associated with primary in fertility. Fertil Steril 2004; 82: 1091–4.
69. Ryan GL, Stolpen A, Van Voorhis BJ. An unusual cause of adolescent dysmenorrhea. Obstet Gynecol 2006; 108 (4): 1017–22.
70. Dietrich JE. An update on adenomyosis in the adolescent. Curr Opin Obstet Gynecol 2010; 22: 388–92.
71. Pontis A, D'Alterio MN, Pirarba S et al. Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol 2016; p. 1–5.
72. Vercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol 2013; 10: 261–75.
73. Johnson NP, Hummelshoj L. Consensus on current management of endometriosis. World Endometriosis Society Montpellier Consortium. Hum Reprod 2013; 28 (6): 1552–68.
74. Meresman GF, Augé L, Barañao RI et al. Oral contraceptives suppress cell proliferation and enhance apoptosis of eutopic endometrial tissue from patients with endometriosis. Fertil Steril 2002; 77 (6): 1141–7.
75. Shimizu Y, Mita S, Takeuchi T et al. Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system. Steroids 2011; 76 (1–2): 60–7.
76. Caruso S, Iraci M, Cianci S et al. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Invest 2016; 39 (8): 923–31.
77. Ferrero S, Remorgida V, Venturini PL, Bizzarri N. Endometriosis: the effects of dienogest. BMJ Clin Evid 2015; 2015. pii: 0802.
78. Soliman AM, Yang H, Du EX et al. The direct and indirect costs associated with endometriosis: a systematic literature review. Hum Reprod 2016; 31 (4): 712–22.
79. Berlanda N, Somigliana E, Viganò P, Vercellini P. Safety of medical treatments for endometriosis. Expert Opin Drug Saf 2016; 15 (1): 21–30.
80. Zhou C, Zhang T, Liu F et al. The differential expression of mRNAs and long noncoding RNAs between ectopic and eutopic endometria provides new insights into adenomyosis. Mol Biosyst 2016; 12 (2): 362–70.
81. Tong X, Li Z, Wu Y et al. COMT 158G/A and CYP1B1 432C/G polymorphisms increase the risk of endometriosis and adenomyosis: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2014; 179: 17–21.
82. Herndon CN, Aghajanova L, Bayalan S et al. Global Transcriptome Abnormalities of the Eutopic Endometrium From Women With Adenomyosis. Reprod Sci 2016.
83. Wang Y, Qu Y, Song W. Genetic variation in COX-2 -1195 and the risk of endometriosis and adenomyosis. Clin Exp Obstet Gynecol 2015; 42 (2): 168–72.
84. Benedetto C. Eicosanoids in primary dysmenorrhea, endometriosis and menstrual migraine. Gynecol Endocrinol 1989; 3 (1): 71–94.
85. Ferenczy A. Pathophysiology of adenomyosis. Hum Reprod Update 1998; 4 (4): 312–22.
86. Brosens I, Derwig I, Brosens J et al. The enigmatic uterine junctional zone: the missing link between reproductive disorders and major obstetrical disorders? Hum Reprod 2010; 25 (3): 569–74.
87. Ibrahim MG, Chiantera V, Frangini S et al. Ultramicro-trauma in the endometrial-myometrial junctional zone and pale cell migration in adenomyosis. Fertil Steril 2015; 104 (6): 1475–83.e1-3.
88. Leyendecker G, Bilgicyildirim A, Inacker M et al. Adenomyosis and endometriosis. Re-visiting their association and further insights into the mechanisms of auto-traumatisation. An MRI study. Arch Gynecol Obstet 2015; 291 (4): 917–32.

________________________________________________

1. Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical review. Hum Reprod Update 2015; 21 (6): 762–78.
2. Osayande AS, Mehulic S. Diagnosis and initial management of dysmenorrhea. Am Fam Physician 2014; 89 (5): 341–6.
3. Mrugacz G, Grygoruk C, Sieczyński P et al. Etiopathogenesis of dysmenorrhea. Med Wieku Rozwoj 2013; 17 (1): 85–9.
4. Ortiz MI. Primary dysmenorrhea among Mexican university students: prevalence, impact and treatment. Eur J Obstet Gynecol Reprod Biol 2010; 152 (1): 73–7.
5. Wong LP, Khoo EM. Dysmenorrhea in a multiethnic population of adolescent Asian girls. Int J Gynaecol Obstet 2010; 108 (2): 139–42.
6. Pitangui AC, Gomes MR, Lima AS et al. Menstruation disturbances: prevalence, characteristics, and effects on the activities of daily living among adolescent girls from Brazil. J Pediatr Adolesc Gynecol 2013; 26: 148–52.
7. Ayan M, Sogut E, Tas U et al. Pain levels associated with renal colic and primary dysmenorrhea: a prospective controlled study with objective and subjective outcomes. Arch Gynecol Obstet 2012; 286: 403–9.
8. Jones AE. Managing the pain of primary and secondary dysmenorrhoea. Nurs Times 2004; 100 (10): 40–3.
9. Ju H, Jones M, Mishra G. The prevalence and risk factors of dysmenorrhea. Epidemiol Rev 2014; 36: 104–13.
10. Berkley KJ, McAllister SL. Don’t dismiss dysmenorrhea! Pain 2011; 152: 1940–1.
11. Pejčić A, Janković S. Risk factors for dysmenorrhea among young adult female university students. Ann Ist Super Sanita 2016; 52 (1): 98–103.
12. Ju H, Jones M, Mishra G. A U-Shaped Relationship between Body Mass Index and Dysmenorrhea: A Longitudinal Study. PLoS One 2015; 10 (7).
13. Iacovides S, Baker FC, Avidon I, Bentley A. Women with dysmenorrhea are hypersensitive to experimental deep muscle pain across the menstrual cycle. J Pain 2013; 14 (10): 1066–76.
14. Vincent K, Warnaby C, Stagg CJ et al. Dysmenorrhoea is associated with central changes in otherwise healthy women. Pain 2011; 152: 1966–75.
15. Ye R, Wang S, Li Y et al. Primary dysmenorrhea is potentially predictive for initial orthodontic pain in female patients. Angle Orthod 2014; 84 (3): 424–9.
16. Juang CM, Yen MS, Twu NF et al. Impact of pregnancy on primary dysmenorrhea. Int J Gynaecol Obstet 2006; 92 (3): 221–7.
17. Ju H, Jones M, Mishra G. The prevalence and risk factors of dysmenorrhea. Epidemiol Rev 2014; 36: 104–13.
18. Hayaishi O, Matsumura H. Prostaglandins and sleep. Adv Neuroimmunol 1995; 5: 211–6.
19. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol 2006; 108: 428–41.
20. Coco AS. Primary dysmenorrhea. Am Fam Physician 1999; 60: 489–96.
21. Nigam S, Benedetto C, Zonca M et al. Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. Eicosanoids 1991; 4 (3): 137–41.
22. Harel Z. Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea. J Pediatr Adolesc Gynecol 2004; 17: 75–9.
23. Altunyurt S, Gol M, Altunyurt S et al. Primary dysmenorrhea and uterine blood flow: a color Doppler study. J Reprod Med 2005; 50: 251–5.
24. Loram LC, Mitchell D, Skosana M, Fick LG. Tramadol is more effective than morphine and amitriptyline against ischaemic pain but not thermal pain in rats. Pharmacol Res 2007; 56: 80–5.
25. Tu CH, Niddam DM, Chao HT et al. Abnormal cerebral metabolism during menstrual pain in primary dysmenorrhea. Neuroimage 2009; 47: 28–35.
26. Tu CH, Niddam DM, Chao HT et al. Brain morphological changes associated with cyclic menstrual pain. Pain 2010; 150: 462–8.
27. Ma H, Hong M, Duan J et al. Altered cytokine gene expression in peripheral blood monocytes across the menstrual cycle in primary dysmenorrhea: a case-control study. PLoS One 2013; 8.
28. Iacovides S, Avidon I, Bentley A, Baker FC. Reduced quality of life when experiencing menstrual pain in women with primary dysmenorrhea. Acta Obstet Gynecol Scand 2014; 93: 213–7.
29. Driver HS, Baker FC. Menstrual factors in sleep. Sleep Med Rev 1998; 2: 213–29.
30. Chantler I, Mitchell D, Fuller A. Actigraphy quantifies reduced voluntary physical activity in women with primary dysmenorrhea. J Pain 2009; 10: 38–46.
31. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 163: 2433–45.
32. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum 2008; 37: 339–52.
33. Woolf CJ. Central sensitization: uncovering the relation between pain and plasticity. Anesthesiol 2007; 106: 864–7.
34. Engeler DS, Baranowski AP, Dinis-Oliveira P et al; The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development. Eur Urol 2013; 64 (3): 431–9.
35. Ortiz MI, Cortés-Márquez SK, Romero-Quezada LC et al. Effect of a physiotherapy program in women with primary dysmenorrhea. Eur J Obstet Gynecol Reprod Biol 2015; 194: 24–9.
36. Yu S, Yang J, Yang M et al. Application of acupoints and meridians for the treatment of primary dysmenorrhea: a data mining-based literature study. Evid Based Complement Alternat Med 2015; 752194.
37. Shah M, Monga A, Patel S et al. The effect of hypnosis on dysmenorrhea. Int J Clin Exp Hypn 2014; 62 (2): 164–78.
38. Ziaei S, Zakeri M, Kazemnejad A. A randomised controlled trial of vitamin E in the treatment of primary dysmenorrhoea. BJOG 2005; 112 (4): 466–9.
39. Zekavat OR, Karimi MY, Amanat A, Alipour F. A randomised controlled trial of oral zinc sulphate for primary dysmenorrhea in adolescent females. Aust N Z J Obstet Gynaecol 2015; 55 (4): 369–73.
40. Zahradnik HP, Hanjalic-Beck A, Groth K. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception 2010; 81: 185–96.
41. Campbell MA, McGrath PJ. Non-pharmacologic strategies used by adolescents for the management of menstrual discomfort. Clin J Pain 1999; 15: 313–20.
42. Sherif BQ, Al-Zohyri AM, Shihab SS. Effects of Some Non Steroidal Anti-inflammatory Drugs on Ovulation in Women with Mild Musculoskeletal Pain (A Clinical Study). IOSR-JPBS 2014; 9 (4; Ver. IV): 43–9.
43. Mendonça LL, Khamashta MA, Nelson-Piercy C et al. Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology (Oxford) 2000; 39 (8): 880–2.
44. Lindh I, Milsom I. The influence of intrauterine contraception on the prevalence and severity of dysmenorrhea: a longitudinal population study. Hum Reprod 2013; 28: 1953–60.
45. Ekelund M, Melander M, Gemzell-Danielsson K. Intrauterine contraception: attitudes, practice, and knowledge among Swedish health care providers. Contraception 2014; 89: 407–12.
46. Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev 2001.
47. Ruoff G, Lema M. Strategies in pain management: new and potential indications for COX-2 specific inhibitors. J Pain Symptom Manage 2003; 25: S21–S31.
48. Strowitzki T, Kirsch B, Elliesen J. Efficacy of ethinylestradiol 
20 mg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study. J Fam Plann Reprod Health Care 2012; 38: 94–101.
49. Harada T, Momoeda M, Terakawa N et al. Evaluation of a low-dose oral contraceptive pill for primary dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2011; 95 (6): 1928–31.
50. Ottová B, Weiss P. Mental changes in women due to the use of hormonal contraception. [Article in Czech]. Ceska Gynekol 2015; 80 (5): 355–9.
51. Cheslack-Postava K, Keyes KM, Lowe SR, Koenen KC. Oral contraceptive use and psychiatric disorders in a nationally representative sample of women. Arch Womens Ment Health 2015; 18 (1): 103–11.
52. Tanaka Y, Mori T, Ito F et al. Effects of low-dose combined drospirenone-ethinylestradiol on perimenstrual symptoms experienced by women with endometriosis. Int J Gynaecol Obstet 2016. pii: S0020-7292(16)30256-9.
53. Momoeda M, Hayakawa M, Shimazaki Y et al. Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women. Int J Womens Health 2014; 6: 989–98.
54. Zelenay S, Reis E, Sousa C. Reducing prostaglandin E2 production to raise cancer immunogenicity. Oncoimmunology 2016; 5 (5): e1123370.
55. Eberhart CE, Coffey RJ, Radhika A et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107 (4): 1183–8.
56. Pockaj BA, Basu GD, Pathangey LB et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 2004; 11 (3): 328–39.
57. Wallace AE, Sales KJ, Catalano RD et al. Prostaglandin F2alpha-F-prostanoid receptor signaling promotes neutrophil chemotaxis via chemokine (C-X-C motif) ligand 1 in endometrial adenocarcinoma. Cancer Res 2009; 69 (14): 5726–33.
58. Tong BJ, Tan J, Tajeda L et al. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia 2000; 2 (6): 483–90.
59. Jabbour HN, Milne SA, Williams AR et al. Expression of COX-2 and PGE synthase and synthesis of PGE(2) in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br J Cancer 2001; 85 (7): 1023–31.
60. Wallace AE, Gibson DA, Saunders PT, Jabbour HN. Inflammatory events in endometrial adenocarcinoma. J Endocrinol 2010; 206 (2): 141–57.
61. Babic A, Cramer DW, Titus LJ et al. Menstrual pain and epithelial ovarian cancer risk. Cancer Causes Control 2014; 25 (12): 1725–31.
62. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol 2015; 16 (9): 1061–70.
63. Beral V, Doll R, Hermon C et al.; Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371 (9609): 303–14.
64. McLaughlin JR, Risch HA, Lubinski J et al. Hereditary Ovarian Cancer Clinical Study Group. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007; 8 (1): 26–34.
65. Bosetti C, Bravi F, Negri E, La Vecchia C. Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Reprod Update 2009; 15 (5): 489–98.
66. Bird CC, McElin TW, Manalo-Estrella P. The elusive adenomyosis of the uterus-revisited. Am J Obstet Gynecol 1972; 112: 583–93.
67. Lee NC, Dicker RC, Rubin GL, Ory HW. Confirmation of the preoperative diagnoses for hysterectomy. Am J Obstet Gynecol 1984; 150: 283–7.
68. Barrier BF, Malinowski MJ, Dick EJ Jr et al. Adenomyosis in the baboon is associated with primary in fertility. Fertil Steril 2004; 82: 1091–4.
69. Ryan GL, Stolpen A, Van Voorhis BJ. An unusual cause of adolescent dysmenorrhea. Obstet Gynecol 2006; 108 (4): 1017–22.
70. Dietrich JE. An update on adenomyosis in the adolescent. Curr Opin Obstet Gynecol 2010; 22: 388–92.
71. Pontis A, D'Alterio MN, Pirarba S et al. Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol 2016; p. 1–5.
72. Vercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol 2013; 10: 261–75.
73. Johnson NP, Hummelshoj L. Consensus on current management of endometriosis. World Endometriosis Society Montpellier Consortium. Hum Reprod 2013; 28 (6): 1552–68.
74. Meresman GF, Augé L, Barañao RI et al. Oral contraceptives suppress cell proliferation and enhance apoptosis of eutopic endometrial tissue from patients with endometriosis. Fertil Steril 2002; 77 (6): 1141–7.
75. Shimizu Y, Mita S, Takeuchi T et al. Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system. Steroids 2011; 76 (1–2): 60–7.
76. Caruso S, Iraci M, Cianci S et al. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Invest 2016; 39 (8): 923–31.
77. Ferrero S, Remorgida V, Venturini PL, Bizzarri N. Endometriosis: the effects of dienogest. BMJ Clin Evid 2015; 2015. pii: 0802.
78. Soliman AM, Yang H, Du EX et al. The direct and indirect costs associated with endometriosis: a systematic literature review. Hum Reprod 2016; 31 (4): 712–22.
79. Berlanda N, Somigliana E, Viganò P, Vercellini P. Safety of medical treatments for endometriosis. Expert Opin Drug Saf 2016; 15 (1): 21–30.
80. Zhou C, Zhang T, Liu F et al. The differential expression of mRNAs and long noncoding RNAs between ectopic and eutopic endometria provides new insights into adenomyosis. Mol Biosyst 2016; 12 (2): 362–70.
81. Tong X, Li Z, Wu Y et al. COMT 158G/A and CYP1B1 432C/G polymorphisms increase the risk of endometriosis and adenomyosis: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2014; 179: 17–21.
82. Herndon CN, Aghajanova L, Bayalan S et al. Global Transcriptome Abnormalities of the Eutopic Endometrium From Women With Adenomyosis. Reprod Sci 2016.
83. Wang Y, Qu Y, Song W. Genetic variation in COX-2 -1195 and the risk of endometriosis and adenomyosis. Clin Exp Obstet Gynecol 2015; 42 (2): 168–72.
84. Benedetto C. Eicosanoids in primary dysmenorrhea, endometriosis and menstrual migraine. Gynecol Endocrinol 1989; 3 (1): 71–94.
85. Ferenczy A. Pathophysiology of adenomyosis. Hum Reprod Update 1998; 4 (4): 312–22.
86. Brosens I, Derwig I, Brosens J et al. The enigmatic uterine junctional zone: the missing link between reproductive disorders and major obstetrical disorders? Hum Reprod 2010; 25 (3): 569–74.
87. Ibrahim MG, Chiantera V, Frangini S et al. Ultramicro-trauma in the endometrial-myometrial junctional zone and pale cell migration in adenomyosis. Fertil Steril 2015; 104 (6): 1475–83.e1-3.
88. Leyendecker G, Bilgicyildirim A, Inacker M et al. Adenomyosis and endometriosis. Re-visiting their association and further insights into the mechanisms of auto-traumatisation. An MRI study. Arch Gynecol Obstet 2015; 291 (4): 917–32.

А.Л.Унанян*1, И.С.Сидорова1, А.Д.Никонец1, Ю.В.Костина1, Н.Н.Кузенкова2,3, А.М.Елисаветская4, Д.В.Бабурин1

1. ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
2. ГБУЗ «Городская поликлиника №68» Департамента здравоохранения г. Москвы. 119180, Россия, Москва, ул. Малая Якиманка, д. 22, стр. 1;
3. ФГАОУ ВО «Российский университет дружбы народов». 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6;
4. Женская консультация №7 филиала ГБУЗ «Городская клиническая больница №1 им. Н.И.Пирогова» Департамента здравоохранения г. Москвы «Родильный дом №25». 115184, Россия, Москва, Озерковская наб., д. 42/2
*9603526@mail.ru

________________________________________________

A.L.Unanian*1, I.S.Sidorova1, A.D.Nikonets1, Yu.V.Kostina1, N.N.Kuzenkova2,3, A.M.Elisavetskaia4, D.V.Baburin1

1. I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
2. Сity Clinical Hospital №68 of the Department of Health of Moscow. 119180, Russian Federation, Moscow, ul. Malaia Iakimanka, d. 22, str. 1;
3. People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaya, d. 6;
4. Women's Consultation №7 of the Maternity Hospital №25, the branch of N.I.Pirogov City Сlinical Hospital №1 of the Department of Health of Moscow. 115184, Russian Federation, Moscow, Ozerkovskaia nab., d. 42/2
*9603526@mail.ru